Hi, everyone. Welcome to the A6 and Z podcast. I'm Sonal. Today we have one of our reruns, which was recorded during the JPMorgan Healthcare Conference last year, where the A6 and Z Bio Team had a lot and has a lot going on this year as well. And it's with Voss Neurosimmon, the CEO of Navartis, one of the largest healthcare and pharmaceutical companies in the world.

In terms of volume, they're the largest producer of medicines, with 70 billion doses a year

across a wide range of therapeutic areas from cancer to cardiovascular disease and more.

Joining me to interview him are A6 and Z general partners Jorge Condé and VJ Pande from the A6 and Z bio team,

and we cover the latest trends in therapeutics, including the journey in chemistry and medicine,

from large molecules and antibodies and proteins to small molecules and other new modalities with

RNA and now moving more into the cell and gene engineered world.

We also cover when science becomes engineering and what does that mean at an industry and a

big company innovation level. And then we touch on topics such as clinical trials, healthcare

go-to-market, shifts in talent in the landscape, and startups working with big pharma.

But we begin with the business of science with R&D and innovation, both inside and out.

You build up R&D expertise in our industry over long periods of time.

If you think about cardiovascular disease, we've been in it 40, 50 years.

When you think about transplant and immunology, again, 40, 50 years,

oncology, 25 years.

So you build up an accumulated expertise.

And really the art of it is to make sure you have a depth of new medicines to keep filling your pipeline in each one of those therapeutic areas.

Now, there are instances where we find new breakthroughs and areas we're not in.

Those you have to really think about, are you going to really stay in that area for the long term?

The other element of the story is when you really have exhausted your pipeline.

We're not so good as an industry at this, but you have to also be prepared to exit, I think, areas where you're going to be subscale.

And that's something

...